SCHEMBL21451065

SCHEMBL21451065

Nc1nc2ccccc2c2c(=O)c3cc(F)ccc3sc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPI P34949 2/20 0.39
PMM2 O15305 1/20 0.39
PHOSPHO1 Q8TCT1 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TOP1 P11387 1/20 0.39
TOP2A P11388 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
GLA P06280 1/20 0.38
TLR8 Q9NR97 3/20 0.37
TLR7 Q9NYK1 3/20 0.37
ADORA2A P29274 3/20 0.36
ADORA3 P0DMS8 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21450906 0.85 TOP1 (0.43) MPIPMM2PHOSPHO1APOBEC3GTLR9
SCHEMBL17655671 0.85 KDM4E (0.52) TOP1TOP2ATLR8TLR7ADORA2A
SCHEMBL21875194 0.82 KDM4E (0.55) L3MBTL1ADORA2AADORA3KMT2AMEN1
SCHEMBL16374499 0.82 TOP1 (0.39) TOP1TOP2ATLR8TLR7KDM4E
SCHEMBL21451024 0.81 NPC1 (0.43) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL21451006 0.81 TOP1 (0.45) MPIPMM2PHOSPHO1APOBEC3GTLR9
SCHEMBL30089850 0.80 PRKCI (0.38) TOP1TOP2AL3MBTL1GLAKDM4E
SCHEMBL21875232 0.80 PRKCI (0.38) TOP1TOP2AL3MBTL1GLAKDM4E
SCHEMBL21450998 0.79 TOP1 (0.56) TOP1TOP2AL3MBTL1GLATLR7
SCHEMBL21450992 0.78 TOP1 (0.43) MPIPMM2PHOSPHO1APOBEC3GTLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 MPI 1310/4885PMM2 3233/4885PHOSPHO1 4512/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 MPI 1310/4885PMM2 3233/4885PHOSPHO1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.